Dear Subscriber,
Welcome to the December Newsletter from the Stem Cells Portal - the online resource and community for researchers, brought to you by the Stem Cells Journal. We have recently redesigned our Newsletter to more effectively bring you the latest news and updates from the Stem Cells Portal. We hope you enjoy it! Please also take a moment to join our new Stem Cells Community, where you can edit your own profile page and interact with other community members.
You may unsubscribe to this newsletter by using the Safe Unsubscribe link at the bottom of this announcement.
Stem Cells Portal Editor,
AlphaMed Press
| Happy Holidays
|
Stem Cells would like to take this opportunity to wish everyone Happy Holidays, with all the best for the New Year.
"The most exciting phrase to hear in science, the one that heralds new discoveries, is not 'Eureka!' (I found it!) but 'That's funny ...'"
(Isaac Asimov)
| | Press Release |
Partnership for Stem Cells journal
Media Contact:
Amy Molnar
P: 201-748-8844
E: amolnar@wiley.com
Media Contact:
Ann Murphy
P: 919-680-0011 (Ext. 229)
E: AnnMurphy@AlphaMedPress.com
For Immediate Release
Wiley-Blackwell and AlphaMed Press Announce New Co-Publishing
Partnership for Stem Cells journal
Hoboken, NJ, and Durham, NC, July 28, 2008- Wiley-Blackwell, the scientific, technical, medical and scholarly publishing business of John Wiley & Sons, Inc. and AlphaMed Press today announced that Wiley-Blackwell has been selected to serve as co-publisher of Stem Cells.
Stem Cells, the international journal of cell Differentiation and Proliferation, is co-edited by Dr. Donald G. Phinney and Dr. Miodrag Stojković and a global editorial board. The Journal publishes peer-accepted original articles and concise reviews describing basic laboratory investigations of stem cells and the translation to patient care. It also provides a forum for young investigators to present provocative proposals for new research directions. The journal covers all aspects of stem cells and Regenerative Medicine including Embryonic Stem Cells; induced Pluripotent stem cells; tissue-specific stem cells; cancer stem cells; the stem cell niche; stem cell epigenetics, genomics and proteomics; translational and clinical research; and technology development. With an Impact Factor of 7.531 Stem Cells is in the top 3% of all high impact international journals.
"We are proud to have engaged Wiley-Blackwell as our co-publisher of Stem Cells effective January 1, 2009. For the past twenty-six years the journal Stem Cells has been the premier journal devoted exclusively to stem cell biology and its clinical applications," reflected Ann Murphy, PhD., President of AlphaMed Press. By partnering with Wiley-Blackwell, a highly respected publisher with worldwide reach, the Journal's impact will be enhanced and, in turn, it will foster research that offers such promise."
Wiley-Blackwell serves as publisher for over 750 publishing partners, providing the scholarly community with access to the highest-quality content available. "Through AlphaMed Press' visionary work, Stem Cells has made an enormous impact on development of the field of stem cell science and regenerative medicine," said Colette E. Bean, Publisher. "In collaboration, we expect to make considerable advances in the content and delivery of information, which we hope will have a lasting and profound benefit to the stem cells scientific community."
For more information about Stem Cells visit: www.StemCells.com
About AlphaMed Press
Established in 1983, AlphaMed Press with offices in Durham, NC and Craigavon, United Kingdom publishes two internationally renowned peer-reviewed journals: Stem Cells®, now in its 26th year, is the world's first journal devoted to this fast paced field of research. The Oncologist® (www.TheOncologist.com), also a monthly peer-reviewed publication, is in its 13th year and is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. Both journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines. AlphaMed Press publishes the Stem Cells Portal online (www.StemCellsPortal.com), as well as freestanding monographs and books, and is renowned for its excellence and speed in the publication of the peer-reviewed proceedings of major international symposia.
About Wiley-Blackwell
Wiley-Blackwell was formed in February 2007 as a result of the acquisition of Blackwell Publishing Ltd. by John Wiley & Sons, Inc., and its merger with Wiley's Scientific, Technical, and Medical business. Together, the companies have created a global publishing business with deep strength in every major academic and professional field. Wiley-Blackwell publishes approximately 1,400 scholarly peer-reviewed journals and an extensive collection of books with global appeal. For more information on Wiley-Blackwell, please visit www.blackwellpublishing.com or http://interscience.wiley.com.
About Wiley
Founded in 1807, John Wiley & Sons, Inc. has been a valued source of information and understanding for 200 years, helping people around the world meet their needs and fulfill their aspirations. Since 1901, Wiley and its acquired companies have published the works of more than 350 Nobel laureates in all categories: Literature, Economics, Physiology/Medicine, Physics, Chemistry and Peace.
Our core businesses include scientific, technical, medical and scholarly journals, encyclopaedias, books, and online products and services; professional/trade publishes books, subscription products, training materials, and online applications and websites; and educational materials for undergraduate and graduate students and lifelong learners. Wiley's global headquarters are
located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company's Web site can be accessed at http://www.wiley.com. The Company is listed on the New York Stock Exchange under the symbols JWa and JWb.
| | Celebrating 10 Years of hESC Cell Lines |
Ten years ago this November, a paper was published that led to an explosion in the field of stem cell research. In November 1998, Dr. James Thomson's laboratory reported the first derivation of human embryonic stem cell (hESC) lines from human blastocysts (Science 1998;282:1145-1147).
To celebrate this landmark discovery, and to look forward to the future of stem cell research, STEM CELLS has begun an interview series titled "Celebrating 10 Years of hESC Cell Lines". Over the next several months, STEM CELLS will present interviews reflecting on the lives and achievements of some of the premiere scientists in the field of stem cells and regenerative medicine. This month, we are happy to present "An Interview with Rudolf Jaenisch".
Throughout the series, each lab will also be featured on the "Stem Cells Portal - Featured Labs" and the Portal will also carry additional excerpts from each interview.
Read the Introductory Editorial to this series from Dr. Miodrag Stojkovic, Co-Editor of Stem Cells, in the November issue of STEM CELLS.
Read our interview with Dr. Jaenisch in the November issue of STEM CELLS.
Read more about Dr. Jaenisch's lab, featured on the Stem Cells Portal.
Read additional excerpts from our interview with Dr. Jaenisch, available only on the Stem Cells Portal.
Join our Discussion Forum - "With the advent of iPS cells, is generating ESCs from embryos still important?"
| | Featured Labs - Dr. Rudolf Jaenisch |
 
Contact Information: Rudolf Jaenisch, M.D. Founding Member, Whitehead Institute Professor of Biology. Massachusetts Institute of Technology Department of Biology Whitehead Institute Nine Cambridge Center Cambridge, MA 02142-1479 Assistant: Gerry Kemske phone: 617.258.5189 kemske@wi.mit.edu Celebrating 10 Years of hESC Cell Lines Ten years ago this November, a paper was published that led to an explosion in the field of stem cell research. In November 1998, Dr. James Thomson's laboratory reported the first derivation of human embryonic stem cell (hESC) lines from human blastocysts (Science 1998;282:1145-1147). To celebrate this landmark discovery, and to look forward to the future of stem cell research, Stem Cells has begun an interview series titled "Celebrating 10 Years of hESC Cell Lines". Over the next several months, STEM CELLS will present interviews reflecting on the lives and achievements of some of the premiere scientists in the field of stem cells and Regenerative Medicine. The series continues here with "An Interview with Rudolf Jaenisch". Read the Introductory Editorial to this series from Dr. Miodrag Stojkovic, Co-Editor of Stem Cells, in the November issue of STEM CELLS. Read our interview with Dr. Jaenisch in the November issue of STEM CELLS. Read additional excerpts from our interview with Dr. Jaenisch, available only on the Stem Cells Portal. Join our Discussion Forum - "With the advent of iPS cells, is generating ESCs from embryos still important?" Lab Feature Overview of the Jaenisch Lab: "What makes a given cell a given cell-what makes a liver cell a liver cell versus a brain cell versus an embryonic cell?" asks Rudolf Jaenisch. "We want to understand this in molecular terms, and we are using this information to convert one cell type into another." Jaenisch, a Whitehead Founding Member, focuses on understanding epigenetic regulation of Gene expression (the biological mechanisms that affect how genetic information is converted into cell structures but that don't alter the genes in the process). Most recently, this work has led to major advances in our understanding of embryonic stem cells and "induced Pluripotent stem" (IPS) cells, which appear identical to Embryonic Stem Cells but can be created from adult cells without using an egg. Research in the Jaenisch Lab Publications (from PubMed) Selected Achievements Video - Dr. Jaenisch Discusses "Creating iPS cells using the cancer gene c-Myc" (From the Whitehead Institute) Video - Dr. Jaenisch discusses "Making iPS cells from B cells" (From the Whitehead Institute News Archives) Video - Dr. Jaenisch Discusses " Using iPS derived nerve cells in a Parkinson's disease model" (From the Whitehead Institute News Archives) Article: Dr. Jaenisch discusses : "New technique produces genetically identical stem cells" (From the Whitehead Institute News Archives) The Whitehead Institute for Biomedical Research MIT - Department of Biology Jaensich Lab page at The Whitehead Institute Jaensich Lab page at Massachusetts Institute of Techology | Featured Resource - The Stem Cell Bank of Barcelona (BLCB)
|
Contact Information:
E-mail: cmrb@cmrb.eu
website: http://www.cmrb.eu/banco-lineas-celulares/en_index.html
About the BLCB
The Stem Cell Bank of Barcelona (BLCB) is a functional unit of the CMR[B], dedicated to the derivation, maintenance, characterisation and preservation of embryonic stem cells, with the aim of developing research activities in the area of regenerative medicine. In terms of infrastructure, the Bank comprises cell culture, characterisation and cryobiology laboratories.
The principal midterm objective of the BLCB project will be to achieve the capacity to create cell lines free from xenobiotics and in GMP conditions to obtain material useable in clinical research. The close collaboration between the BLCB and the CMRB research laboratory will enable an optimisation of the cultive conditions with the aim of carrying out research in the therapeutic field.
 Dedicated to the derivation, maintenance, characterisation and preservation de embryo stem cells, with the aim of developing research activities in the area of regenerative medicine. Its mission will be to generate a record of stem-cell lines, with the aim of improving research in the area of embryo stem cells with its own research project
Available Lines and their Characterization:
Research Topics:
Leadership and Personnel
FAQs
Image Gallery
The CRM[B] homepage
| | Video - Meet Dr. Miodrag Stojkovic's Lab |
 Visit the Portal Video Archive to see more videos, including stem cell lectures, general information, and our new section, 'Stem Cell Labs'. Send us a video to introduce your lab! Contact: portaleditor@alphamedpress.com | Top 10 Read and Cited Articles from
Stem Cells for November | | | Upcoming Meeting Highlights
|
  Call for Posters Deadline: 11 December 2008 Agenda Topics - Cancer Stem Cells
- Stem Cell Epigenetics
- Stem Cells in Drug Discovery and Development
- Regenerative Medicine
- Pluripotency, iPSC
- SPECIAL SESSION: Biobanking
At the 2009 conference, you will learn about:- Design precision diagnostic tools and identify disease biomarkers (MOLECULAR DIAGNOSTICS)
- Reduce late-stage attrition through translational biomarkers, more predictive models, and earlier proof-of-concept studies (TRANSLATIONAL MEDICINE)
- Use genomic, proteomic and pathway information to identify the best drug targets (CANCER PROFILING AND PATHWAYS)
- Optimize the design of therapeutic agents, including small- and large-molecules, (MEDICINAL CHEMISTRY, PRECLINICAL DEVELOPMENT OF BIOLOGICS)
- Explore cell-based therapeutics including the latest advances in stem cell therapies
- (STEM CELL THERAPIES, PRECLINICAL DEVELOPMENT OF BIOLOGICS)
- Map intricate pathways and identify drug intervention points
- (CANCER PROFILING AND PATHWAYS)
- Develop safer therapeutics that can flourish in the market with reduced chance of adverse events (PRECLINICAL DRUG SAFETY)
- Generate effective business and diversification strategies to maximize progress with problematic targets and diseases ( EXECUTIVE SUMMIT)
- Leverage informatics tools and strategies to improve R&D success (IT TRACK)
For 16 years, CHI's MOLECULAR MEDICINE TRI-CONFERENCE has tracked the growth, the challenges and opportunities in this space. Molecular medicine can solve the looming healthcare crisis and increase productivity and success in Pharma and Biotech. The 2009 event promises to be the most critical and successful event yet. Attend to participate in a highly interactive, strategically focused program, lead by a panel of 60+ sector leaders, including: - Dr. Ajan Reginald, Global Head of Emerging Technologies, Roche Group Research
- Kimberly A. Benton, PhD, Deputy Director, Division of Cellular & Gene Therapies, OCTGT/CBER, US FDA
- Stephen Potter, Senior VP, Corporate Development, Genzyme Corporation
- Dr. John McNeish, Executive Director, Regenerative Medicine, Pfizer
- Dr. Rajesh Chopra, Global Medical Science Director, Emerging Products, AstraZeneca
- Dr. C. Randal Mills, President & CEO, Osiris Therapeutics, Inc
- Dr. Sudha Kadiyala, Worldwide Director, Business Development & Strategic Planning, Johnson & Johnson
- Dr. Gopalan Narayanan, Manager & Head, Biologicals & Biotechnology Unit, Medicines & Healthcare Products Regulatory Agency (MHRA)
- Dr. Alan J. Lewis, President & CEO, Novocell Inc
- Shosh Merchav, PhD, MBA, Director, Head, Cell Therapy Projects, Teva Innovative Venture, Teva Pharmaceutical Industries Ltd
- John T. Dimos, PhD, Senior Scientist, iZumi Bio Inc
- Brock C. Reeve, Executive Director, Harvard Stem Cell Institute
- Howard J. Leonhardt, Chairman, CEO & CTO, Bioheart, Inc
- Bruce Wentworth, PhD, Director - Science, MG Biotherapeutics, Director of Research, Genzyme
- Dr. Ann Tsukamoto, COO, StemCells, Inc
Visit www.phacilitate.co.uk/cgtherapy for the latest program information and online registration. E-mail team@phacilitate.co.uk or call +44 (0)20 7839 6137 with any queries. Contact Nicola McCall at nicola@phacilitate.co.uk (Tel: +44 (0)20 7839 6137) for sponsorship/booth information. GTCbio's 5th annual conference on Stem Cell Research & Therapeutics provides stem cell researchers with a comfortable environment to exchange ideas and brainstorm on novel pathways to discovery. Leading experts in the field will present unreleased information and attendees will learn the most up-to-date developments in this arena. Register early as attendance is limited to ensure optimal networking and discussion.  
ESF-EMBO SymposiumCELL POLARITY AND MEMBRANE TRAFFIC Cell polarity and vesicle sorting are fundamental biological processes that impact stem cell function, cancer, bacterial and viral infections, developmental defects and neurological diseases. A wide range of topics connect polarity with membrane transport, including mRNA transport and epithelial cell polarization, membrane identity and apical/basolateral membrane sorting, axon specification and transport in neurons, vesicle sorting during polarization in budding and fission yeast, and the involvement of membrane traffic in the establishment of polarity in organogenesis. Computational modeling, high throughput screens and revolutionary imaging technologies in multiple model organisms are being applied to these areas and will have a major impact in the future. The time is opportune to bring scientists working in these areas together, to encourage interactions, build new collaborations and push the field forward. Since this is an emerging, interdisciplinary field, we want to attract young people to the meeting and provide ample opportunities to present their work and meet with scientific leaders. We will therefore include short talks chosen from abstracts and provide enough time for informal discussions to foster interactions among the participants.
ESF-FWF Conference in Partnership with LFUIThe Impact of the Environment on Innate Immunity: The Threat of Diseases The threat of diseases: considering the options - is the second in a series of two conferences on the impact of the environment on innate immunity. The first conference was held in April 2007, and set the stage for discussing basic knowledge about one of the most important defense functions of organisms against parasitic diseases: the innate immune system. In May 2009 the follow-up conference will build upon the knowledge gained in the 2007conference and will have a more applied angle. Its highlights will include vectors of disease - both an introduction to the model organisms, and what the prospects are for immunological interference in these organisms; innate defense molecules for use as antibiotics, environmental stressors and global change, emerging disease and innate immunity, and how our knowledge can be used to develop strategies against the spread of new diseases. | | Contact Us/Add Your Resources and Announcements |
Our aim is to bring together a network of stem cell researchers, resources, and information, to encourage and stimulate research. We would like to partner with you to feature: - work from your stem cell lab
- stem cells resources that you can share with our community
- announcements from your lab/institution
- upcoming meetings and events
- new stem cell research products
- highlights of the news and literature
To find out more about becoming a part of our Portal please contact the Portal Editor. | | | | | |
